阿片使用障碍药物治疗联合mHealth干预对成瘾行为的影响:一项随机临床试验
该随机对照试验纳入414例接受阿片使用障碍药物治疗(MOUD)的门诊患者,比较MOUD单用与MOUD联合A-CHESS智能手机干预16个月并随访8个月的效果。总体两组非法阿片使用戒断率无差异(OR=1.10,95%CI=0.90-1.33),但戒断率受戒断症状严重程度和MOUD类型调节,且联合组会议出席率更高、急诊和紧急护理使用更少。
要点
- MOUD联合A-CHESS与单用MOUD相比,总体非法阿片戒断率无显著差异(OR=1.10,95%CI=0.90-1.33)。
- 无戒断症状者中联合组戒断率更高(OR=1.30,95%CI=1.01-1.67);美沙酮亚组联合组戒断概率随时间增加更明显。
- 联合组会议出席率更高(OR=1.25,95%CI=1.05-1.49),急诊和紧急护理使用更少(OR=0.88,95%CI=0.78-0.99)。
核心结论
- 总体而言,MOUD联合A-CHESS并未较单用MOUD改善非法阿片戒断,但可能对部分患者亚组有益并影响治疗利用。
研究设计与样本
- 非盲平行组随机对照试验,从门诊项目招募414例参与者,按1:1分配至单用MOUD组或MOUD+A-CHESS组,干预16个月并额外随访8个月。
- 所有参与者使用美沙酮、丁丙诺啡或注射纳曲酮;主要结局为非法阿片使用戒断,次要结局包括治疗保留、卫生服务使用、其他物质使用和生活质量。
- 调节因素包括MOUD类型、性别、戒断症状严重程度、疼痛严重程度和孤独感;数据来源为每4个月一次包含多个验证量表的调查及尿检。
主要发现
- MOUD+A-CHESS组与单用MOUD组非法阿片戒断随时间无差异(OR=1.10,95%CI=0.90-1.33)。
- 戒断受戒断症状严重程度(OR=0.95,95%CI=0.91-1.00)和MOUD类型(OR=0.57,95%CI=0.34-0.97)调节。
- 无戒断症状者中,联合组随时间戒断率高于单用组(OR=1.30,95%CI=1.01-1.67)。
- 美沙酮使用者中,联合组戒断随时间增加(b=0.28,SE=0.09),单用组为(b=0.06,SE=0.08),两组间差异不显著(∆b=0.22,SE=0.11)。
- 联合组会议出席率更高(OR=1.25,95%CI=1.05-1.49),急诊和紧急护理使用减少(OR=0.88,95%CI=0.78-0.99)。
临床怎么用
- 对于无戒断症状或使用美沙酮的MOUD患者,可考虑联合A-CHESS以潜在改善戒断结局。
- 联合A-CHESS可能提高治疗参与度并减少急诊和紧急护理使用,可作为辅助支持工具。
局限性
- 研究为非盲设计,可能引入偏倚。
- 结果基于特定门诊样本和16个月干预,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Medication for opioid use disorder (MOUD) improves treatment retention and reduces illicit opioid use. A-CHESS is an evidence-based smartphone intervention shown to improve addiction-related behaviors. The authors tested the efficacy of MOUD alone versus MOUD plus A-CHESS to determine whether the combination further improved outcomes. METHODS: In an unblinded parallel-group randomized controlled trial, 414 participants recruited from outpatient programs were assigned in a 1:1 ratio to receive either MOUD alone or MOUD+A-CHESS for 16 months and were followed for an additional 8 months. All participants were on methadone, buprenorphine, or injectable naltrexone. The primary outcome was abstinence from illicit opioid use; secondary outcomes were treatment retention, health services use, other substance use, and quality of life; moderators were MOUD type, gender, withdrawal symptom severity, pain severity, and loneliness. Data sources were surveys comprising multiple validated scales, as well as urine screens, every 4 months. RESULTS: There was no difference in abstinence between participants in the MOUD+A-CHESS and MOUD-alone arms across time (odds ratio=1.10, 95% CI=0.90-1.33). However, abstinence was moderated by withdrawal symptom severity (odds ratio=0.95, 95% CI=0.91-1.00) and MOUD type (odds ratio=0.57, 95% CI=0.34-0.97). Among participants without withdrawal symptoms, abstinence rates were higher over time for those in the MOUD+A-CHESS arm than for those in the MOUD-alone arm (odds ratio=1.30, 95% CI=1.01-1.67). Among participants taking methadone, those in the MOUD+A-CHESS arm were more likely to be abstinent over time (b=0.28, SE=0.09) than those in the MOUD-alone arm (b=0.06, SE=0.08), although the two groups did not differ significantly from each other (∆b=0.22, SE=0.11). MOUD+A-CHESS was also associated with greater meeting attendance (odds ratio=1.25, 95% CI=1.05-1.49) and decreased emergency department and urgent care use (odds ratio=0.88, 95% CI=0.78-0.99). CONCLUSIONS: Overall, MOUD+A-CHESS did not improve abstinence relative to MOUD alone. However, MOUD+A-CHESS may provide benefits for subsets of patients and may impact treatment utilization.
引用
- Gustafson DH, Landucci G, Vjorn OJ, et al. Effects of Bundling Medication for Opioid Use Disorder With an mHealth Intervention Targeting Addiction: A Randomized Clinical Trial. Am J Psychiatry. 2023. PMID: 37789744. doi:10.1176/appi.ajp.20230055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。